← Back to Search

Cohort 2 for Alzheimer's Disease

N/A
Recruiting
Led By Sanbrita Mondal, OD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one month post baseline
Awards & highlights

Study Summary

The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are: Whether the test is as effective and reliable as the standard test Whether there is a link between the results of the smell test and the structure of the back of the eye Participants will: complete a short questionnaire have pictures of the inside of their eyes taken perform two smell tests

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month post baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month post baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Compare ScentAware test results conducted with support from clinical staff to the test results when ScentAware test was self-administered independently
Compare UPSIT test results conducted with support from clinical staff to the test results when ScentAware test was self-administered independently
Compare test scores of ScentAware olfactory test to the scores of the University of Pennsylvania Smell Identification Test (UPSIT) olfactory test in a clinical setting
Secondary outcome measures
Compare baseline ScentAware test scores between cohorts
Compare baseline ScentAware test scores to the ganglion cell layer (GCL) thickness
Compare baseline ScentAware test scores to the retinal nerve fiber layer (RNFL) thickness
+3 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3Experimental Treatment2 Interventions
Mild cognitive impairment due to Alzheimer's disease
Group II: Cohort 2Experimental Treatment2 Interventions
No cognitive impairment, with a family history of Alzheimer's disease
Group III: Cohort 1Experimental Treatment2 Interventions
No cognitive impairment, and no family history of Alzheimer's disease

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,190 Previous Clinical Trials
3,169,597 Total Patients Enrolled
Sanbrita Mondal, ODPrincipal InvestigatorUniversity of Wisconsin, Madison
Kathleen Schildroth, MDPrincipal InvestigatorUniversity of Wisconsin, Madison

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
ScentAware and OCT in MCI vs HC
2024. "ScentAware and OCT in MCI vs HC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06377241.
All > Milwaukee
~0 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top